Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common blood pressure drug slow type 1 diabetes?

NCT ID NCT04545151

Disease control Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether verapamil, a drug usually used for high blood pressure, can help preserve insulin-making cells in adults newly diagnosed with type 1 diabetes. 136 participants received either verapamil or a placebo for 12 months. The main goal was to see if verapamil could maintain the body's ability to produce insulin, measured by a C-peptide test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Verapamil SR (a blood pressure medication)
What this could lead to
If it works, this could point toward a way to preserve insulin production in people newly diagnosed with type 1 diabetes, potentially slowing the disease.
What could go wrong
This is a phase 2 trial with only 136 participants, so results are preliminary. Verapamil is not a cure and may not meaningfully change long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

136 people

The number who actually took part.

Started

Feb 2021

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have given written informed consent * Age ≥18 and \<45 at consent * Must have a diagnosis of T1D of within 6 weeks duration at screening (date of the first insulin injection) * Must have at least one or more diabetes-related autoantibodies present at screening: GADA, IA-2A and/or ZnT8A * Must have fasting C-peptide levels ≥100 pmol/L measured at screening * Be willing to comply with intensive diabetes management Exclusion Criteria: * Be immunodeficient or have clinically significant chronic lymphopenia: Leukopenia (\< 3,000 leukocytes /µL), neutropenia (\<1,500 neutrophils/µL), lymphopenia (\<800 lymphocytes/µL), or thrombocytopenia (\<100,000 platelets/µL) * Have active signs or symptoms of acute infection at the time of screening * Be currently pregnant or lactating, or anticipate getting pregnant during the 12 months study period * Require use of immunosuppressive agents including chronic use of systemic steroids * Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection * Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, chronic obstructive pulmonary disease (COPD), sickle cell disease, neurological, or blood count abnormalities as judged by the investigator * Have a history of malignancies other than skin * History of liver insufficiency or laboratory evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limits of normal * History of renal insufficiency or evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal * Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control within prior 7 days of screening * Use of any other investigational drug in the previous 30 days and/or intent on using any investigational drug for the duration of the trial * Current use of Verapamil or other calcium channel blockers * Known hypersensitivity to Verapamil or to any of its excipients * Concomitant medication known for significantly inducing or inhibiting CYP3A4 and/or glycoprotein-P metabolism * Intake of grapefruit juice, licorice, St.John's Wort, cannabidiol, ginkgo biloba * Substrate intake of CYP3A4 and/or glycoprotein-P metabolism, as judged by the investigator * Hypotension (of less than 100mmHg systolic), sick sinus syndrome (except patients with a functioning artificial pacemaker), uncompensated heart failure or severe left ventricular dysfunction; marked bradycardia (less than 50 beats/minute), atrial flutter or atrial fibrillation in the presence of an accessory bypass tract (e.g. Wolff-Parkinson-White syndrome), hypertrophic cardiomyopathy, acute myocardial infarction, attenuated neuromuscular transmission (e.g. by myasthenia gravis, Lambert-Eaton syndrome, advanced Duchenne muscular dystrophy) * ECG second or third degree atrioventricular block; Incomplete branch block * Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results * Current use of ß-blockers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1

Contacts and locations

Locations

  • Addenbrokes Hospital

    Cambridge, United Kingdom

  • Bart's Hospital QMUL

    London, United Kingdom

  • Guy's Hospital

    London, United Kingdom

  • HKA Hannover

    Hanover, Germany

  • Institut National de la Santé et de la Recherche Médicale

    Paris, France

  • John Radcliffe Hospital

    Oxford, United Kingdom

  • Katholieke Universiteit Leuven

    Leuven, Belgium

  • Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism

    Graz, Styria, 8010, Austria

  • NHS Greater Glasgow and Clyde-Queen Elizabeth University Hospital, Department of Diabetes

    Glasgow, United Kingdom

  • OCDEM, John Radcliffe Hospital

    Oxford, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Queens Medical Centre

    Nottingham, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

  • Singleton Hospital

    Swansea, United Kingdom

  • Southmead Hospital

    Bristol, United Kingdom

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • University Hospital of Wales

    Cardiff, United Kingdom

  • Università Vita-Salute San Raffaele

    Milan, Italy

  • Università degli Studi di Siena

    Siena, Italy

  • Universität Ulm

    Ulm, Germany

  • Université Libre de Bruxelles/ Hôpital Erasme

    Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.